Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

作者：Benjamini Ohad; Jain Preetesh; Trinh Long; Qiao Wei; Strom Sara S; Lerner Susan; Wang Xuemei; Burger Jan; Ferrajoli Alessandra; Kantarjian Hagop; O'Brien Susan; Wierda William; Estrov Zeev; Keating Michael^*

来源：Leukemia and Lymphoma, 2015, 56(6): 1643-1650.

DOI：10.3109/10428194.2014.957203

• Lymphoid leukemia
• pharmacotherapeutics
• chemotherapeutic approaches

Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence of second cancers, but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear. We report on the characteristics, incidence, outcomes and factors associated with second cancers in 234 patients receiving fludarabine, cyclophosphamide and rituximab (FCR) based regimens in the frontline setting.The risk of second cancers was 2.38 times higher than the expected risk in the general population. Ninety-three patients (40%) had other cancers before and 66 patients (28%) after FCR. Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5.1%) and Richter transformation (RI) (9%) were high, while solid tumors were not increased. Overall survival of patients with second cancers after frontline FCR was shorter (median of 4.5 years) compared to patients with and without prior cancers. Second cancer risk after frontline FCR is mainly due to high rates of t-AMUMDS and RI, and as speculated the survival of affected patients is shorter.

• 出版日期2015-6